A randomized, prospective single center clinical trial to compare the cognitive improvement effects of electroacupuncture and computerized cognitive rehabilitation for mild cognitive impairment

Dongshin University0 个研究点目标入组 64 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•1. an elderly aged between 55 and 85 years
•2. impaired memory lasting for at least 3 months meeting the diagnostic criteria for MCI
•3. Global Deterioration scale score of 2 or 3
•4. Korean version of Mini-Mental State Examination(K-MMSE) score of 20–23
•5. Korean version of Montreal Cognitive Assessment scale (MoCA-K) score of 0-22
•6. Geriatric Depression Scale (GDS) score of 0-18
•7. at least six years of education or adequate Korean language proficiency for reliable study assessments
•8. voluntary provision of informed consent.

•1. Diagnosis of vascular dementia according to the NINDS-AIREN criteria or diagnosis of AD according to the NINCDS-ADRDA criteria
•2. a history of structural brain lesions that could cause cognitive decline, such as congenital mental retardation, stroke, traumatic brain injury, or intracranial space-occupying lesions
•3. presence of a serious illness (e.g., Huntington disease, Parkinson's disease, cancer, central nervous system, liver, cardiovascular, and kidney diseases, and multiple sclerosis)
•4. a history of brain diseases confirmed on brain magnetic resonance imaging or computed tomography within 12 months
•5. history of treatment for drug or alcohol dependency or mental illness (schizophrenia, serious anxiety, or depression) within 6 months prior to screening
•6.current treatment for MCI, such as Korean medicine treatment, medication, or cognitive training within 4 weeks before screening
•7. difficulties in undergoing outcome measurement due to visual and hearing impairments
•8. unfitness for electroacupuncture (e.g., blood-clotting abnormalities such as hemophilia, scalp infection, and presence of a pacemaker)
•9. pregnancy or breastfeeding
•10. A people who is participating in other trials or has participated in other trials within 8 weeks prior to screening

发起方